1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma

Technology appraisal guidance [TA478] Published date: 04 October 2017

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...

Tools and resources

Tools to help you put the guidance into practice.

Resource impact

  • Resource impact statement  

Guidance into practice

  • About the Into practice guide  
  • Practical steps to improving the quality of care and services using NICE guidance